期刊
LEUKEMIA & LYMPHOMA
卷 57, 期 4, 页码 797-802出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1088651
关键词
signal transduction; cholesterol; HMG-CoA reductase inhibitor; lipoprotein; Chronic lymphocytic leukemia; inflammation; statin
资金
- Canadian Institutes of Health Research [190633] Funding Source: Medline
The incidence of hypercholesterolemia and its possible relationship with clinical course were determined by reviewing the records of 231 consecutive patients presenting to a specialized Chronic Lymphocytic Leukemia (CLL) clinic. Evidence for elevated cholesterol was found in up to 174/231 patients (75%) based on existing use of statins (107 patients) or non-fasting low-density lipoprotein cholesterol levels greater than 2.5 mM. Excluding patients with 17p deletions, time to first treatment (TFT) was prolonged if patients were taking cholesterol-lowering statins (57.5 (IQR = 32, 77) vs 36 (IQR = 11, 100) months, p < 0.02). If patients were prescribed statins after being diagnosed with CLL, TFT was longer than if they were taking statins before the diagnosis. These observations suggest there is a high incidence of hypercholesterolemia in CLL patients and cholesterol-lowering may impact the disease course.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据